Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Meena, Thayu"'
Autor:
Nicolas Girard, Keunchil Park, Se-Hoon Lee, Santiago Viteri, Claudio A. Schioppa, Joris Diels, Mustafa Oguz, Bernardo H. Rodrigues, Nora Rahhali, Jan Sermon, Francesca Ghilotti, Tracy Li, Meena Thayu, Roland E. Knoblauch, Parthiv Mahadevia, Byoung Chul Cho
Publikováno v:
Cancer Treatment and Research Communications, Vol 40, Iss , Pp 100832- (2024)
Background: Amivantamab, an EGFR-MET bispecific antibody, is the first approved targeted therapy for patients with EGFR Ex20ins NSCLC after prior platinum-based chemotherapy—a population with historically poor outcomes before amivantamab approval.
Externí odkaz:
https://doaj.org/article/b0e636fa219d41078d74b8b155ecc004
Autor:
Keunchil Park, Joshua K. Sabari, Eric B. Haura, Catherine A. Shu, Alexander Spira, Ravi Salgia, Karen L. Reckamp, Rachel E. Sanborn, Ramaswamy Govindan, Joshua M. Bauml, Joshua C. Curtin, John Xie, Amy Roshak, Patricia Lorenzini, Dawn Millington, Meena Thayu, Roland E. Knoblauch, Byoung Chul Cho
Publikováno v:
Lung Cancer. 178:166-171
Autor:
Rathi N. Pillai, MD, Suresh S. Ramalingam, MD, Meena Thayu, MD, Patricia Lorenzini, RN, Diana A. Alvarez Arias, PhD, Christopher Moy, MS, Natalie Hutnick, PhD, Roland Knoblauch, MD, Huaibao Feng, PhD, Colleen Kane, PhD, Leora Horn, MD, Martin Reck, MD, Santiago Ponce, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 2, Pp 100104- (2021)
Introduction: The programmed death-ligand 1 inhibitor atezolizumab improves progression-free survival (PFS) and overall survival (OS) for patients with previously treated advanced NSCLC. Preclinical studies indicate that targeting CD38-positive cells
Externí odkaz:
https://doaj.org/article/004fca5ad8a2446e9fa4ccca4e835923
Autor:
Meena Thayu, A. Roshak, Jose Manuel Trigo, Jong Seok Lee, Keunchil Park, Santiago Viteri, Ramaswamy Govindan, Natasha B. Leighl, Ji-Youn Han, Paul Mitchell, Nahor Haddish-Berhane, James Chih-Hsin Yang, Chee Khoon Lee, Roland Elmar Knoblauch, Patricia Lorenzini, Byoung Chul Cho, Dawn Millington, Nicolas Girard, Alexander I. Spira, Tsung-Ying Yang, Rachel E. Sanborn, Eric B. Haura, J.C. Curtin, Matthew G Krebs, Pilar Garrido, Koichi Goto, Sang-We Kim, Dong Wan Kim, Karen L. Reckamp, Ki Hyeong Lee, Joshua Bauml, Joshua K. Sabari, Catherine A. Shu, John Xie
Publikováno v:
Park, K, Haura, E, Leighl, N B, Mitchell, P, Shu, C, Girard, N, Viteri, S, Han, J-Y, Kim, S-W, Lee, C K, Sabari, J, Spira, A, Yang, T-Y, Kim, D-W, Lee, K H, Sandborn, R, Trigo, J, Goto, K, Lee, J-S, Yang, J C-H, Govindan, R, Bauml, J M, Garrido, P, Krebs, M, Reckamp, K, Xie, J, Curtin, J, Haddish-Berhane, N, Roshak, A, Millington, D, Lorenzini, P, Thayu, M, Knoblauch, R & Cho, B C 2021, ' Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.21.00662
PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with
Autor:
Paul Eliezer Oberstein, Cathy Eng, Eric Van Cutsem, Elena Elez, Michel Ducreux, Sejal Patel, Dona Pang, Leann Milford, Ryota Iwasawa, Robert W. Schnepp, Roland Knoblauch, Meena Thayu
Publikováno v:
Journal of Clinical Oncology. 41:TPS279-TPS279
TPS279 Background: Amivantamab, a fully human EGFR and MET bispecific antibody, has shown clinical activity against tumors with primary activating EGFR mutations, EGFR resistance mutations, or MET pathway activation. Amivantamab has demonstrated acti
Autor:
A. Roshak, Chae Won Park, Matthew V. Lorenzi, Seong Gu Heo, Min Hee Hong, Mi Ran Yun, Sun Min Lim, Soo-Hwan Lee, Meena Thayu, Kyoung Ho Pyo, Byoung Chul Cho, Seo Yoon Jeong, Hye Ryun Kim, Seok Young Kim, S.M. Lim, J.C. Curtin, Jiyeon Yun, Jae Hwan Kim, Roland Elmar Knoblauch
Publikováno v:
Cancer Discovery. 10:1194-1209
EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR–MET, has shown preclinical activi
Autor:
Keunchil Park, Joshua Sabari, Eric B. Haura, Catherine A. Shu, Alexander Spira, Ravi Salgia, Karen L. Reckamp, Rachel E. Sanborn, Ramaswamy Govindan, Joshua M. Bauml, Joshua C. Curtin, John Xie, Amy Roshak, Patricia Lorenzini, Dawn Millington, Meena Thayu, Roland E. Knoblauch, Byoung Chul Cho
Publikováno v:
Annals of Oncology. 33:S482
Autor:
Matthew G Krebs, Grace Gao, S-H.I. Ou, Meena Thayu, Jose Manuel Trigo, Jonathan H. Goldman, Anna Minchom, R.W. Schnepp, Benjamin Besse, Alexander I. Spira, Aaron S. Mansfield, A. Roshak, Pasi A. Jänne, Z. Wang, Byoung Chul Cho, Z. Ma, J.C. Curtin, Chee Khoon Lee, Ravi Salgia, Roland Elmar Knoblauch
Publikováno v:
Journal of Thoracic Oncology. 16:S874-S875
Autor:
Catherine A. Shu, Koichi Goto, Yuichiro Ohe, Benjamin Besse, Se-Hoon Lee, Yongsheng Wang, Frank Griesinger, James Chih-Hsin Yang, Enriqueta Felip, Rachel E. Sanborn, Reyes Bernabe Caro, Joshua C Curtin, Jun Chen, Janine M. Mahoney, Leonardo Trani, Joshua Michael Bauml, Roland Elmar Knoblauch, Meena Thayu, Byoung Chul Cho
Publikováno v:
Journal of Clinical Oncology. 40:9006-9006
9006 Background: Initial results with the amivantamab (ami) and lazertinib (laz) regimen showed encouraging efficacy in patients (pts) whose disease progressed after standard-of-care osimertinib (osi) and platinum-based chemotherapy (pt-chemo; Shu An
Autor:
Matthew Krebs, Alexander I. Spira, Byoung Chul Cho, Benjamin Besse, Jonathan W. Goldman, Pasi A. Janne, Zhiyong Ma, Aaron Scott Mansfield, Anna Rachel Minchom, Sai-Hong Ignatius Ou, Ravi Salgia, Zhijie Wang, Casilda Llacer Perez, Grace Gao, Joshua C Curtin, Amy Roshak, Robert W. Schnepp, Meena Thayu, Roland Knoblauch, Chee Khoon Lee
Publikováno v:
Journal of Clinical Oncology. 40:9008-9008
9008 Background: Amivantamab, a fully human bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET, is approved for the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion after prior platinum-based chem